Skip to main content

Ultra-Rapid Molecular-Genetic Assays Feasible for Tumor Classification During Surgery

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on March 3, 2025.

via HealthDay

MONDAY, March 3, 2025 -- Intraoperative ultra-rapid droplet digital polymerase chain reaction (UR-ddPCR) can identify tumor genetic subtype and quantify tumor cell percentage with high accuracy, according to a study published online Feb. 25 in Med.

Zachary R. Murphy, Ph.D., from the New York University Grossman School of Medicine in New York City, and colleagues introduced UR-ddPCR to examine its feasibility for use during surgery and whether the workflow can reduce the time from tissue biopsy to molecular diagnosis.

The researchers developed a UR-ddPCR assay for the IDH1 R132H mutation that accurately measured the mutant DNA percentage down to 0.1 percent, which was concordant with standard ddPCR. In addition, a UR-ddPCR assay was developed for the BRAF V600E mutation. The clinical feasibility of UR-ddPCR was assessed by intraoperative use in 22 brain tumor cases, with multiple tissue samples per case (78 samples). The tissue samples were used for UR-Stimulated Raman Histology and UR-ddPCR. There was high concordance for tumor cell percentages measured by intraoperative UR-ddPCR with standard ddPCR performed on the sample lysates. Raman histologic images provided real-time measurement of total cellularity, with tumor cell densities ranging from >1,300 to <5 tumor cells/mm2 within the core and at tumor margins, respectively. The UR-ddPCR results were achieved in an average of 14 minutes and 39 seconds and 17 minutes and seven seconds for IDH1 R132H and BRAF V600E assays, respectively.

"Our study shows that ultra-rapid droplet digital PCR could be a fast and efficient tool for making a molecular diagnosis during surgery for brain cancer," co-senior author Gilad D. Evrony, M.D., Ph.D., also from the New York University Grossman School of Medicine, said in a statement.

Several authors disclosed ties to the biopharmaceutical and medical device industries; several authors are listed on a provision patent on the technology. Reagents and instruments were provided by Bio-Rad.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Sense of Life Purpose Lowers Risk for Cognitive Impairment

THURSDAY, Sept. 4, 2025 -- A sense of purpose in life (PiL) is associated with a lower risk for and later onset of cognitive impairment, according to a study published online in...

Risk for Second Cancer Low for Women Treated for Early, Invasive Breast Cancer

THURSDAY, Sept. 4, 2025 -- The risk for second primary cancers is higher for breast cancer survivors than for women in the general population; however, the risk remains low and is...

Paternal Prepubertal Passive Smoke Exposure Impacts Offspring Lung Function

THURSDAY, Sept. 4, 2025 -- Paternal passive smoke exposure before completing puberty may intergenerationally impair lung function in future generations, according to a study...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.